| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Preclinical Development | Executive Vice President
1 company
Holsinger Leslie is an EVP, Preclinical Development at Quince Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 6 sells.
Estimated insider holdings value: $140K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 14, 2020 | QNCX Quince Therapeutics, Inc. | Executive Vice President | Sale+OE | 40,000 | $30.81 | $1,232,528.00 | -30.0% |